Public Notifications

Search

Search Results

Search Again
Pharmacist Registrant 35 (Apr 8, 2022)

Pharmacist Registrant 35 has satisfied the terms of a Consent Agreement reached with the Inquiry Committee on February 22, 2019. Limits and conditions on the pharmacist registrant’s registration as a pharmacist have now been removed by the Inquiry Committee. The pharmacist registrant’s name has been withheld pursuant to s. 39.3(4) of the Health Professions Act.

February 22, 2019
(April 8, 2022 - Limits and conditions removed)

The Inquiry Committee has reinstated the pharmacist registrant’s registration which had previously been suspended for an indefinite period on March 6, 2018. Pursuant to Section 36(1) of the Health Professions Act, the Inquiry Committee has reached an Agreement with the pharmacist registrant whereby the pharmacist registrant consented to terms including, but not limited to, the following:

  1. To strictly adhere to the their routine medical monitoring program with the institution currently involved in their care and remaining on the monitoring program for the stated period of time;
     
  2. To comply with any and all recommendations and treatment prescribed or directed by medical professionals involved in their care;
     
  3. For the first year after returning to work as a pharmacist, to not work alone in a pharmacy, and to have another pharmacist in good standing supervising them at all times;
     
  4. To not handle, physically prepare, or dispense prescriptions for narcotic drugs, sedative hypnotics, stimulants, testosterone, cyclobenzaprine or other habit forming, short acting mood-altering or potentially habit forming prescription medications at any time;
     
  5. To not have any access whatsoever, on or off duty, to the narcotic safe in any pharmacy;
     
  6. To inform all managers and employers with whom the Registrant gains employment of their medical condition and the limits and conditions on registration pursuant to the Agreement;
     
  7. To ensure that all managers and employers with whom the Registrant gains employment submits a written statement to the College declaring their awareness of the Registrant's medical condition and the Agreement, and how they will accommodate and supervise the Registrant working in the pharmacy; and
     
  8. To inform the College in via e-mail of their places of employment as a pharmacist and report any changes to the location of their employment within 48 hours of such change.
March 6, 2018
(February 22, 2019 - Registration Reinstated)

The Inquiry Committee, pursuant to Section 32.2(4)(b)(ii) of the Health Professions Act, has reached an agreement with the pharmacist registrant to suspend his registration as a pharmacist for an indefinite period pending further disposition of the Inquiry Committee. The Inquiry Committee considers the agreement necessary to protect the public. The pharmacist registrant's name has been withheld pursuant to 39.3(4) of the Health Professions Act. 

Vincent, Alain (Apr 5, 2022)

  1. Nature of Action: The Inquiry Committee of the College of Pharmacists of British Columbia (“CPBC”) conducted an investigation into the practice of Alain Vincent (the “Registrant”), pursuant to section 33(4) of the Health Professions Act, R.S.B.C. 1996, c. 183.

    The Inquiry Committee and the Registrant have agreed to resolve all matters arising from the investigation by way of a Consent Agreement under section 36(1) of the Health Professions Act.

  2. Effective date: April 5, 2022

  3. Name of registrant: Alain Vincent

  4. Location of Practice: Victoria, BC

  5. Admissions and acknowledgements:

    The Registrant has admitted and/or acknowledged the following:

    1. Between February 13 and June 30, 2021, while he was the pharmacy manager, the Registrant and other pharmacy staff processed 80 prescription transactions that had an incorrect dispensed quantity and/or incorrect directions for use.
       
    2. The Registrant and other pharmacy staff did not enter prescription information and record it in PharmaNet at the time of dispensing and keep the patient record current for prescriptions involved in the matter, contrary to section 35(1) of the Pharmacy Operations and Drug Scheduling Act, S.B.C. 2003, c. 77 (“PODSA”) Bylaws.
       
    3. The Registrant and other pharmacy staff did not complete an adequate final check of the prescriptions involved in the matter and did not take appropriate action respecting a drug therapy problem, contrary to sections 6(5)(e) and 10(6) of the Health Professions Act, R.S.B.C. 1996, c.183 (“HPA”), Bylaws, Schedule F, Part 1 – Community Pharmacy Standards of Practice (“Standards of Practice”).
       

    4. As the pharmacy manager, the Registrant did not ensure:

      1. That the pharmacy had documented policies and procedures;
         
      2. That narcotic reconciliations were performed pursuant to section 18(2)(s) of the PODSA Bylaws and Professional Practice Policy – 65 Narcotic Counts and Reconciliations (“PPP-65”).

  1. Disposition:

    The Registrant entered into a Consent Agreement with the Inquiry Committee, wherein the Registrant consented to the following terms (in part):

    1. To not be a pharmacy manager and preceptor or supervisor of registered pharmacy students and/or international pharmacy graduates for a period of one year effective on October 5, 2022;

    2. To pay a fine in the amount of $7,500;

    3. To review and abide by applicable legislative standards;

      • Data entry of prescription information;

      • Incident reporting;

      • Managing relationships with physicians;

      • Clinical decision making and documentation;

      • Preventing medication incidents; and

      • Guidelines on mitigating substance-related risks in COVID-19.

  2. Rationale:

    The Inquiry Committee determined that the Registrant and other pharmacy staff did not complete an adequate final check of the prescriptions involved in the incidents as a result of failing to ensure that the correct quantity and directions were transcribed from the original prescription, contrary to sections 10(6), 9.1(1)(a), and 9.1(1)(b) of the Standards of Practice. Therefore, the Inquiry Committee determined that the Registrant and other pharmacy staff failed to enter prescription information and record it in PharmaNet at the time of dispensing and keep the patient record current, contrary to section 35(1) of the PODSA Bylaws.

    The Inquiry Committee determined that in his role as pharmacy manager, the Registrant did not thoroughly investigate the incident and take appropriate action to adequately remediate recurring practice concerns related to the management of the pharmacy, or develop adequate policies and procedures for the operation of a pharmacy. The Inquiry Committee further determined that the Registrant did not ensure that narcotic and controlled drug inventory counts and reconciliations were completed in accordance with the College’s bylaws, legislation, and policies.

    The Inquiry Committee, therefore, considered that the Registrant neglected and disregarded basic duties of a pharmacy manager and that the Registrant’s conduct demonstrated a breach of trust and constituted professional misconduct as defined by section 26 of the Health Professions Act.

    The Inquiry Committee considered the Registrant’s conduct to be serious and that remediation was required to ensure compliance. Therefore, the Inquiry Committee considered the terms of the Consent Agreement necessary and appropriate to protect the public, as well as send a clear message of deterrence to the profession.

Pharmacy Technician Registrant 7 (Mar 17, 2022)

The Inquiry Committee, pursuant to section 32.2(4)(b)(ii) of the Health Professions Act, has reached an Agreement with the registrant to voluntarily suspend their registration as a pharmacy technician effective March 17, 2022. The Agreement remains in effect until further notice. The Inquiry Committee considers the Agreement necessary to protect the public. The registrant’s name has been withheld pursuant to section 39.3(4)(a) of the Health Professions Act.

Loh, Jin Yew (Mar 14, 2022)

  1. Nature of Action: The Inquiry Committee of the College of Pharmacist of British Columbia (the “College”) conducted an investigation into the practice of Jin Yew Loh (the “Registrant”), pursuant to section 33(4) of the Health Professions Act (“HPA”), R.S.B.C. 1996, c. 183. The Inquiry Committee and the Registrant have agreed to resolve all matters arising from the investigation by way of a Consent Agreement under section 36(1) of the HPA.

  2. Effective date: March 14, 2022

  3. Name of registrant: Jin Yew Loh

  4. Location of Practice: Whistler, BC

  5. Admissions and acknowledgements:

    Between November 12th, 2020, and October 13th, 2021, the Registrant falsified prescriptions using two fabricated patient profiles under the authorization of one out-of-province prescriber. The falsified prescriptions resulted in 21 transactions processed onto PharmaNet under these fabricated profiles. The medications included in these transactions were all Schedule I drugs, which required authorized prescriptions. Some of the medications involved included controlled drug substances. The Registrant misappropriated these medications by falsely filling and dispensing them for his own personal use.

    The Registrant used the name and authorization of one out-of-province physician as prescriber on these prescriptions, all without the knowledge, consent, or authorization of this physician. In doing so, the Registrant falsified and inappropriately altered the out-of-province physician’s prescribing records.

  1. Disposition:

    The Registrant entered into a Consent Agreement with the College’s Inquiry Committee, wherein the Registrant consented to terms that include (but are not limited to) the following:

    1. To suspend his registration as a pharmacist for a total of 60 days (May 26, 2022 to July 25, 2022);

    2. To not be pharmacy manager or preceptor for pharmacy students for a period of three years (July 26, 2022 to July 25, 2025);

    3. To write an apology letter to the out-of-province physician affected by this conduct;

    4. To complete and successfully pass an ethics course for healthcare professionals; and

    5. To pay a fine of $1,000.

  2. Rationale:

    The Inquiry Committee considered that in this case, in addition to the serious misconduct, the Registrant created inaccurate prescribing records and placed himself at significant risk of harm by taking unauthorized medication for his personal use. His actions were a serious contravention of standards in the Code of Ethics and compromised the public’s trust in the pharmacy profession as a whole.

    The Inquiry Committee therefore determined that the Registrant required serious remediation and deterrence regarding his conduct. After also considering significant mitigating factors, the Inquiry Committee considered the terms of the Consent Agreement appropriate to protect the public, as well as send a clear message of deterrence to the profession.

Pharmacist Registrant 34 (Mar 4, 2022)

Pharmacist Registrant 34 has satisfied the terms of a Consent Agreement reached with the Inquiry Committee on April 28, 2021. The pharmacist registrant’s name has been withheld pursuant to s. 39.3(4) of the Health Professions Act.

April 28, 2021
(March 4, 2022 - Limits and conditions removed)

Pursuant to Section 36(1) of the Health Professions Act, the Inquiry Committee has reached a new Agreement with the pharmacist registrant whereby the registrant consented to terms including, but not limited to, the following:

  1. To comply with any and all recommendations and treatment prescribed or directed by the physician; and
  2. To attend regular appointments with the physician and comply with random monitoring.  

This Agreement will remain in place until such a time as the pharmacist registrant is reassessed and further recommendations to continue or terminate appointments and/or random monitoring are made by the physician. The name of the pharmacist registrant has been withheld in accordance with Section 39.3(4) of the Health Professions Act.  

May 6, 2020
(April 28, 2021 - Limits and Conditions Updated)

Pursuant to Section 36(1) of the Health Professions Act, the Inquiry Committee has reached a new Agreement with the pharmacist registrant whereby the registrant consented to terms including, but not limited to, the following:

  1. To comply with any and all recommendations and treatment prescribed or directed by the physician; and
     
  2. To attend group meetings, consultations with specialists, and regular monitoring for a period of once year.

This Agreement will remain in place until such a time as the pharmacist registrant is reassessed and further recommendations to continue or terminate consultations and/or regular monitoring are made by the physician. The name of the pharmacist registrant has been withheld in accordance with Section 39.3(4) of the Health Professions Act.  

July 4, 2018
(May 6, 2020 - Limits and Conditions Updated)

The Inquiry Committee has reinstated pharmacist registrant’s registration which had previously be suspended for an indefinite period on February 10, 2018.  Pursuant to section 36(1) of the Health Professions Act, the Inquiry Committee has reached an Agreement with the pharmacist registrant whereby the Registrant consented to undertakings.  The undertakings include, but are not limited to:

  1. The Registrant will comply with any and all recommendations and treatment prescribed or directed by physician; and
     
  2. The Registrant will follow a regular monitoring program for medical condition for a two year period.  

The Agreement will remain in place until such time as the Registrant’s physician states otherwise. The name of the Registrant has been withheld in accordance with section 39.3(4) and (6) of the Health Professions Act for the purposes of not identifying the personal health information of the Registrant. The Inquiry Committee is satisfied that the undertakings will protect the public. 

February 10, 2018
(July 4, 2018 - Registration reinstated)

The Inquiry Committee, pursuant to section 36 of the Health Professions Act, has reached an Agreement with pharmacist registrant to suspend registration as a pharmacist for an indefinite period pending further decision of the Inquiry Committee. The Inquiry Committee considers the Agreement necessary to protect the public. The pharmacist registrant's name has been withheld pursuant to 39.3(4) of the Health Professions Act. 

Pharmacist Registrant 39 (Feb 18, 2022)

Pharmacist Registrant 39 has satisfied the terms of a Consent Agreement reached with the Inquiry Committee on December 19, 2018. The pharmacist registrant’s name has been withheld pursuant to s. 39.3(4) of the Health Professions Act.

December 19, 2018
(February 18, 2022 - Limits and Conditions Removed)

The Inquiry Committee has reinstated pharmacist registrant’s registration which had previously been suspended for an indefinite period on September 24, 2018. Pursuant to section 32.2(4)(b)(i) of the Health Professions Act, the Inquiry Committee has reached an Agreement with the pharmacist registrant whereby the Registrant consented to undertakings. The undertakings include, but are not limited to:

  1. The Registrant will comply with any and all recommendations and treatment prescribed or directed by current physicians;
     
  2. The Registrant undertakes to adhere to routine medical monitoring program with the institution currently involved in the case and remain on the monitoring program for a minimum of 36 consecutive months of uninterrupted and verified abstinence and compliance from the day the Registrant returns to active employment as a pharmacist;
     
  3. In the event of any interruption to the agreed monitoring schedule set out by the medical monitoring program, the Registrant will advise the College of the interruption as soon as possible and provide an explanation for the interruption;
     
  4. The Registrant will not have access whatsoever, on or off-duty, to the narcotic safe in any pharmacy for at least one year from the date the Registrant returns to work;
     
  5. The Registrant will not be involved in any way with ordering mood altering drugs (narcotics, opiates, opioids, benzodiazepines, and atypical sedatives such as zopiclone, zaleplon, and zolpidem and prescription psychostimulants such as dextroamphetamine, methylphenidate and modafinil), except for signing off on the necessary paperwork in the presence of a witnessing pharmacy staff member for the purposes of receiving and stocking such narcotics for at least one year from the date the Registrant returns to work;
     
  6. The Registrant will not handle or physically prepare or dispense prescriptions for mood altering drugs (narcotics, opiates, opioids, benzodiazepines, and atypical sedatives such as zopiclone, zaleplon, and zolpidem and prescription psychostimulants such as dextroamphetamine, methylphenidate and modafinil), except if from time to time this is not possible, then the Registrant can only hand them to the patient and provide patient counselling for at least one year from the date the Registrant returns to work;
     
  7. The Registrant will not dispose or deal with wastage or breakage of or otherwise handle any mood altering drugs (narcotics, opiates, opioids, benzodiazepines, and atypical sedatives such as zopiclone, zaleplon, and zolpidem and prescription psychostimulants such as dextroamphetamine, methylphenidate and modafinil) for at least one year from the date the Registrant returns to work;
     
  8. The Registrant will not dispense own medications;
     
  9. Prior to the commencement of employment at any pharmacy, the Registrant shall disclose to the pharmacy manager and/or employer the limits and conditions on the Registrant’s license pursuant to this Consent Agreement if the pharmacy dispenses mood altering drugs (narcotics, opiates, opioids, benzodiazepines, and atypical sedatives such as zopiclone, zaleplon, and zolpidem and prescription psychostimulants such as dextroamphetamine, methylphenidate and modafinil);
     
  10. The Registrant will ensure that any pharmacy manager and/or employer with whom the Registrant secures employment in a pharmacy that dispenses mood altering drugs (narcotics, opiates, opioids, benzodiazepines, and atypical sedatives such as zopiclone, zaleplon, and zolpidem and prescription psychostimulants such as dextroamphetamine, methylphenidate and modafinil), submits a written statement to the College declaring their awareness of the Registrant’s medical condition and the Agreement. This statement must be received within 48 hours of securing employment and/or within 48 hours of any change of pharmacy manager at the Registrant’s place of employment;
     
  11. The Registrant will inform the College in writing, via e-mail, of  places of employment as a pharmacist and report any changes to the location of employment within 48 hours of such change. A reportable change to the Registrant’s place of employment contemplates both commencement and termination of employment;
     
  12. The Registrant will be restricted from acting in the following roles in the Registrant’s practice:
    1. Be a manager of a pharmacy;
    2. Be a director of a corporation that owns a pharmacy; and
    3. Act as a preceptor of pharmacy students and/or international pharmacy graduates.

This Agreement will remain in place until such time as the Registrant’s physician states otherwise. The name of the Registrant has been withheld in accordance with section 39.3(4)(a) of the Health Professions Act for the purposes of not identifying the personal health information of the Registrant. The Inquiry Committee is satisfied that the undertakings will protect the public.

September 24, 2018
(December 19, 2018 - Registration Reinstated) 

The Inquiry Committee, pursuant to section 32.2(4)(b)(ii) Of the Health Professions Act, has reached an agreement with the pharmacist registrant to voluntarily suspend registration as a pharmacist effective September 24, 2018.  The agreement remains in effect until further notice.  The Inquiry Committee considers the agreement necessary to protect the public.  The pharmacist registrant’s name has been withheld pursuant to section 39.3(4)(a) of the Health Professions Act.

Pharmacist Registrant 22 (Nov 26, 2021)

Pharmacist Registrant 22 has satisfied the terms of a Consent Agreement reached with the Inquiry Committee on November 5, 2020. Limits and conditions on the pharmacist registrant’s registration as a pharmacist have now been removed by the Inquiry Committee. The pharmacist registrant’s name has been withheld pursuant to s. 39.3(4) of the Health Professions Act.

February 21, 2021
(November 26, 2021 - LIMITS AND CONDITIONS Removed)

The Inquiry Committee has approved an amendment to the November 5, 2020 Consent Agreement. The pharmacist registrant is no longer restricted from acting as a preceptor.

November 5, 2020
(February 21, 2021 - Limits and conditions updated)

The Inquiry Committee pursuant to section 36(1) of the Health Professions Act and after consultation with the pharmacist registrant’s physician, has reached an Agreement with the pharmacist registrant to amend some of the terms in the Agreement of June 5, 2019. The pharmacist registrant is now being medically monitored by a different medical provider.

October 22, 2019
(November 5, 2020 - Limits and conditions updated)

The Inquiry Committee has approved an amendment to the June 5, 2019 Consent Agreement. The pharmacist registrant is no longer restricted from being a manager of a pharmacy.

JunE 5, 2019
(October 22, 2019 - LIMITS AND CONDITIONS UPDATED)

The Inquiry Committee, pursuant to section 36(1) of the Health Professions Act and after consultation with the pharmacist registrant’s physician, has reached an Agreement with the pharmacist registrant to amend some of the terms in the Agreement of October 12, 2018. The Registrant can now:

  • work alone in a pharmacy;
  • handle, physically prepare, and dispense prescriptions for opioid medications;
  • have access to the narcotic safe;
  • be involved with ordering narcotic medications.
October 12, 2018
(June 5, 2019 - Limits and Conditions Updated)

The Inquiry Committee has reinstated the pharmacist registrant’s registration which had previously been suspended for an indefinite period on August 13, 2015. Pursuant to Section 36(1) of the Health Professions Act, the Inquiry Committee has reached an Agreement with the pharmacist registrant whereby the pharmacist registrant consented to terms including, but not limited to, the following:

  1. To strictly adhere to the Registrant's routine medical monitoring program with the institution currently involved in the Registrant's care and remaining on the monitoring program for a period of at least 3 years;

  2. To comply with any and all recommendations and treatment prescribed or directed by medical professionals involved in the Registrant's care;

  3. To not work alone in a pharmacy, and to have another pharmacist in good standing supervising the Registrant at all times;

  4. To not handle, physically prepare, or dispense prescriptions for opioid medications at any time;

  5. To not have any access whatsoever, on or off duty, to the narcotic safe in any pharmacy;

  6. To not be involved in any way with ordering narcotic medications, except for signing off on the necessary paperwork in the presence of a witnessing pharmacy staff member for the purposes of receiving and stocking such narcotics;

  7. To inform all managers and employers with whom the Registrant gains employment of his medical condition and the limits and conditions on registration pursuant to the Agreement;

  8. To ensure that all managers and employers with whom the Registrant gains employment submits a written statement to the College declaring their awareness of the Registrant's medical condition and the Agreement, and how they will accommodate and supervise the Registrant working in the pharmacy;
     

  9. To inform the College in via e-mail of his places of employment as a pharmacist and report any changes to the location of his employment within 48 hours of such change; and

  10. To be restricted from acting in the following roles in the Registrant's practice:

    1. Be a manager of a pharmacy;
    2. Be an owner (direct or indirect) of a pharmacy; and
    3. Act as a preceptor.

     

August 13, 2015
(October 12, 2018 – Registration Reinstated)

The Inquiry Committee, pursuant to section 36 of the Health Professions Act, has reached an Agreement with the pharmacist registrant to suspend registration as a pharmacist effective August 13, 2015. The Agreement remains in effect until further notice. The Inquiry Committee considers the Agreement necessary to protect the public. The pharmacist registrant's name has been withheld pursuant to 39.3(4) of the Health Professions Act.

February 13, 2015
(AUGUST 13, 2015 - Registration Suspended)

The Inquiry Committee has reinstated pharmacist registrant’s registration which had previously been suspended for an indefinite period on August 5, 2014. Pursuant to section 36 of the Health Professions Act, the Inquiry Committee has reached an Agreement with the pharmacist registrant whereby the Registrant consented to undertakings involving regular monitoring for fitness to practice pharmacy. The undertakings include, but are not limited to:

  1. Routine and random medical monitoring;

  2. Informing all managers and employers with whom Registrant gains employment of Registrant’s medical condition and the limits and conditions on Registrant’s registration pursuant to the agreement;

  3. Ensuring that all managers and employers with whom Registrant gains employment submits a written statement to the College declaring their awareness of Registrant’s medical condition and the agreement, and how they will accommodate and supervise Registrant working in pharmacy;

  4. Registrant will not work alone in a pharmacy setting, meaning that Registrant must never be the sole pharmacist in attendance at any time and that there must be another pharmacist or pharmacy assistant or pharmacy staff working with Registrant at all times;

  5. Registrant will not have access to narcotic-safe or physically process and/or otherwise prepare any prescriptions that require access to the narcotic safe;

  6. Registrant will not be involved in any way with ordering supplies of narcotic medications;

  7. Registrant will not be involved in the dispensing, ordering, contact, destruction, counting or otherwise handling of opiate medications and other medications with abusive potential;

  8. Being restricted from the following roles in Registrant’s practice:

    1. an owner or manager of a pharmacy;
    2. a director of a corporation that owns a pharmacy; and
    3. a preceptor.

     

  9. Notifying the College of:

    1. all changes in places of employment as a pharmacist
    2. all changes in residential address and phone number; and
    3. all changes in medical provider.

     

The Agreement will remain in place for a minimum of three years of continuous pharmacy practice. The name of the Registrant has been withheld in accordance with section 39.3(4)(a) of the Health Professions Act for the purposes of not identifying the personal health information of the Registrant respecting the condition. The Inquiry Committee is satisfied that the undertakings will protect the public. 

August 5, 2014
(February 13, 2015 – Registration reinstated)

The Inquiry Committee, pursuant to section 36 of the Health Professions Act, has reached an Agreement with the pharmacist registrant to suspend registration as a pharmacist effective August 5, 2014. The Agreement remains in effect until further notice. The Inquiry Committee considers the agreement necessary to protect the public. The pharmacist registrant's name has been withheld pursuant to 39.3(4) of the Health Professions Act.

Pharmacist Registrant 48 (Nov 4, 2021)

The Inquiry Committee has changed the pharmacist registrant’s status to “Full Pharmacist – Active” which had previously been “Full Pharmacist – Suspended” for an indefinite period on December 18, 2020. Pursuant to section 36(1) of the Health Professions Act, the Inquiry Committee has reached an Agreement with the registrant whereby the registrant consented to terms including, but not limited to, the following:

  • To adhere to all steps and comply with all treatment and recovery plans as recommended by their medical provider(s) and/or their most responsible physician(s);
  • To comply and complete all terms of the Relapse Prevention Agreement for a duration of three years and with a graduated return to work over a minimum of seven weeks; and 
  • To authorize and direct any and all caregivers and treating physicians to provide the College with a report and information that relates to the registrant’s health, recovery, and/or treatment plan pertaining to any health condition what could materially impair the registrant’s performance and/or fitness to practice pharmacy.

The Inquiry Committee considers the Agreement necessary to protect the public. The registrant’s name has been withheld pursuant to section 39.3(4) of the Health Professions Act.

December 18, 2020
(November 4, 2021 - Suspension Ended)

The Inquiry Committee, pursuant to section 32.2(4)(b)(ii) of the Health Professions Act, has reached an Agreement with the pharmacist registrant to voluntarily suspend their registration as a pharmacist effective December 18, 2020. The Agreement remains in effect until further notice. The Inquiry Committee considers the Agreement necessary to protect the public. The pharmacist registrant’s name has been withheld pursuant to section 39.3(4)(a) of the Health Professions Act.

Yan, Cheryl Qian (Sep 2, 2021)

The following limits and conditions have now been removed from pharmacist registrant Cheryl Qian Yan’s (the “Registrant”) registration as a pharmacist:

  • Working under direct supervision of a BC pharmacist in good standing;
  • Not working alone; and
  • Not being a supervisor, manager, and/or preceptor.

The Registrant may now work alone and may be a supervisor, manager and/or preceptor.

April 25, 2021
(September 2, 2021 – Limits and Conditions Updated)

Pursuant to s. 36(1) of the Health Professions Act, the Inquiry Committee has reached a revised Agreement with pharmacist registrant Cheryl Qian Yan (the “Registrant”), whereby commencing March 21, 2021, for a specified period of time she must abide by certain limits and conditions on her practice, and she must disclose these limits and conditions to future employers. These limits and conditions include (but are not limited to):

  • Working under direct supervision of a BC pharmacist in good standing;
  • Not working alone;
  • Not being a supervisor, manager, and/or preceptor;
  • Informing employers and the College in writing regarding any medication-related incidents and/or errors that she is involved in; and
  • Notifying the College in writing regarding any changes in employment.

The Inquiry Committee considers these actions necessary to protect the public.

August 10, 2017
(April 25, 2021 - Limits and Conditions Updated)

The Inquiry Committee has deemed Cheryl Qian Yan eligible for reinstatement of her registration, as she has completed and passed the Canadian Pharmacy Practice Programme pursuant to the terms of the Agreement reached on February 24, 2015.

Pursuant to s. 36(1) of the Health Professions Act, the Inquiry Committee has reached a revised Agreement with Ms. Yan, whereby after the reinstatement of her registration, for a specified period of time she must abide by certain limits and conditions on her practice, and she must disclose these limits and conditions to future employers. These limits and conditions include (but are not limited to):

  • Working under direct supervision of a BC pharmacist in good standing;
  • Not working alone;
  • Not being a supervisor, manager, and/or preceptor;
  • Informing employers and the College in writing regarding any medication-related incidents and/or errors that she is involved in; and
  • Notifying the College in writing regarding any changes in employment.

The Inquiry Committee considers these actions necessary to protect the public.

February 24, 2015
(August 10, 2017 – Registration reinstated)

The Inquiry Committee, pursuant to Section 36 of the Health Professions Act, has reached an agreement with Ms. Cheryl Qian Yan where she has voluntarily suspended her pharmacy licence until she has completed and passed the Canadian Pharmacy Practice Programme, and then she will be subject to placing limits and/or conditions on her practice as follows depending on the setting:

  1. If a Hospital Pharmacy or Affiliated Hospital setting:

     

    1. Ms. Yan must work under the direct supervision of a BC licensed pharmacist for a period to three (3) months full time equivalent; where with the current contract, a full time week is 37.5 hours with 7.5 hour work days; and

       

    2. Ms. Yan must not work in a hospital pharmacy or an affiliated pharmacy setting as a pharmacist in a sole practitioner capacity. This means that Ms. Yan must not supervise anyone, direct work, be a manager or a preceptor or pharmacist in charge, for a period to three (3) months full time equivalent; where with the current contract, a full time week is 37.5 hours with 7.5 hour work days.

     

  2. If a Community Pharmacy setting:

     

    1. Ms. Yan will be restricted to process no more than sixty (60) prescriptions daily, within an eight (8) hour shift for a period equivalent to six (6) months full time;

       

    2. Ms. Yan must work under the direct supervision of a BC licensed pharmacist for a period equivalent to three (3) months full time, based on 8 hours per day / 40 hours per week or a total of 480 hours;

       

    3. Ms. Yan must not work in a community pharmacy as a pharmacist in a sole practitioner capacity. This means that Ms. Yan must not supervise anyone, direct work, be a manager or a preceptor or pharmacist in charge, for a period equivalent to three (3) months full time, based on 8 hours per day /40 hours per week or a total of 480 hours; and

       

    4. Ms. Yan will be subject to a practice audit in a community pharmacy of which she must complete and pass during the above six (6) months period mentioned in the above paragraphs 2 (b) and 2 (c).

The Inquiry Committee considers these actions necessary to protect the public.

Pharmacist Registrant 47 (Aug 9, 2021)

The Inquiry Committee has approved to change pharmacist’s registration back to Active status after it had previously been suspended for an indefinite period on December 8, 2020. Pursuant to section 36 of the Health Professions Act, the Inquiry Committee has reached an Agreement with the pharmacist registrant whereby the pharmacist registrant consented to terms including, but not limited to, the following:

  1. To comply with any and all treatment plans as recommended by their medical providers.
     
  2. To comply with any and all return to work plans as advised by their medical providers and/or employers.
     
  3. To voluntarily stop working as a pharmacist and self-report to the College in the event that their  medical condition may hinder their performance and/or fitness to practice as a pharmacist.
     
  4. To authorize and direct any and all caregivers, treating physicians, and/or institution(s) to furnish the College with a written report and any and all information that relates to their health, including a diagnosis, prognosis, status of recovery and/or treatment plan pertaining to their health condition and recovery, when and if necessary for the College to obtain such information.

The pharmacist registrant’s name has been withheld pursuant to section 39.3(4) and (6) of the Health Professions Act.

December 8, 2020
(August 9, 2021 - Registration Reinstated)

The Inquiry Committee, pursuant to section 32.3(3)(b)(ii) of the Health Professions Act, has reached an Agreement with the pharmacist registrant to voluntarily suspend their registration as a pharmacist effective December 8, 2020. The Agreement remains in effect until further notice. The Inquiry Committee considers the Agreement necessary to protect the public. The pharmacist registrant’s name has been withheld pursuant to section 39.3(4)(a) of the Health Professions Act.

Pages